Joel Greenblatt's IONS Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 43,212 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $3.42 M, representing 0.01% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2017, adding 217,756 shares. Largest reduction occurred in Q4 2017, reducing 176,531 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +11,060 | Add 34.40% | 43,212 | $79.11 |
| Q3 2025 | +17,873 | Add 125.17% | 32,152 | $65.42 |
| Q2 2025 | +14,279 | New Buy | 14,279 | $39.51 |
| Q1 2025 | -6,260 | Sold Out | 0 | $0.00 |
| Q4 2024 | -2 | Reduce 0.03% | 6,260 | $34.96 |
| Q2 2024 | -524 | Reduce 7.72% | 6,262 | $47.66 |
| Q1 2024 | -203 | Reduce 2.90% | 6,786 | $43.35 |
| Q4 2023 | -1,099 | Reduce 13.59% | 6,989 | $50.59 |
| Q3 2023 | +23 | Add 0.29% | 8,088 | $45.36 |
| Q2 2023 | -5,168 | Reduce 39.05% | 8,065 | $41.03 |
| Q1 2023 | -56,663 | Reduce 81.07% | 13,233 | $35.74 |
| Q4 2022 | +46,656 | Add 200.76% | 69,896 | $37.77 |
| Q3 2022 | -38,244 | Reduce 62.20% | 23,240 | $44.23 |
| Q2 2022 | +23,057 | Add 60.00% | 61,484 | $37.02 |
| Q1 2022 | +38,427 | New Buy | 38,427 | $37.03 |
| Q2 2020 | -97,992 | Sold Out | 0 | $0.00 |
| Q1 2020 | +43,645 | Add 80.31% | 97,992 | $47.28 |
| Q4 2019 | -148,409 | Reduce 73.20% | 54,347 | $60.41 |
| Q3 2019 | +57,566 | Add 39.65% | 202,756 | $59.93 |
| Q2 2019 | +133,840 | Add 1179.21% | 145,190 | $64.27 |
| Q1 2019 | +11,350 | New Buy | 11,350 | $81.15 |
| Q2 2018 | -32,409 | Sold Out | 0 | $0.00 |
| Q1 2018 | -80,668 | Reduce 71.34% | 32,409 | $44.09 |
| Q4 2017 | -176,531 | Reduce 60.96% | 113,077 | $50.30 |
| Q3 2017 | -67,849 | Reduce 18.98% | 289,608 | $50.70 |
| Q2 2017 | +44,025 | Add 14.05% | 357,457 | $50.87 |
| Q1 2017 | +217,756 | Add 227.60% | 313,432 | $40.20 |
| Q4 2016 | +95,676 | New Buy | 95,676 | $47.83 |
Joel Greenblatt's Ionis Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2016, acquiring 95,676 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Ionis Pharmaceuticals, Inc. (IONS) for 29 quarters since Q4 2016.
Joel Greenblatt's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q1 2017, adding 313,432 shares worth $12.6 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 43,212 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $3.42 M.
As of the Q4 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 357,457 shares, as reported at the end of Q2 2017.